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The bacterial toxin CNF1 as a tool 
to induce retinal degeneration 
reminiscent of retinitis pigmentosa
Viviana Guadagni1, Chiara Cerri1,2, Ilaria Piano3, Elena Novelli1, Claudia Gargini3, 
Carla Fiorentini4, Matteo Caleo1 & Enrica Strettoi1
Retinitis pigmentosa (RP) comprises a group of inherited pathologies characterized by progressive 
photoreceptor degeneration. In rodent models of RP, expression of defective genes and retinal 
degeneration usually manifest during the first weeks of postnatal life, making it difficult to distinguish 
consequences of primary genetic defects from abnormalities in retinal development. Moreover, mouse 
eyes are small and not always adequate to test pharmacological and surgical treatments. An inducible 
paradigm of retinal degeneration potentially extensible to large animals is therefore desirable. Starting 
from the serendipitous observation that intraocular injections of a Rho GTPase activator, the bacterial 
toxin Cytotoxic Necrotizing Factor 1 (CNF1), lead to retinal degeneration, we implemented an inducible 
model recapitulating most of the key features of Retinitis Pigmentosa. The model also unmasks an 
intrinsic vulnerability of photoreceptors to the mechanism of CNF1 action, indicating still unexplored 
molecular pathways potentially leading to the death of these cells in inherited forms of retinal 
degeneration.
Retinitis pigmentosa (RP) includes a group of pathologies in which a mutation, typically in a retinal-specific gene, 
leads to primary rod photoreceptor loss, causing night blindness and reduction of the peripheral visual field1. This 
process is followed by the secondary death of cones, with consequent daytime blindness and loss of color vision 
and visual acuity up to near blindness. As a consequence of photoreceptor degeneration, inner retinal cells also 
undergo a process of regressive remodeling. RP is a rare disease, with an estimated incidence of 1/3,000-1/5,000 
and the first symptoms usually appear during adolescence, with an overall progression that may take several years, 
mainly depending on the underlying mutation; blindness is anyway the inevitable outcome, with no cure yet2,3. 
Various animal models of RP (either naturally occurring or resulting from genetic manipulations) are available 
and actively exploited to study the progression of the pathology, to identify the mechanisms of retinal degen-
eration and to develop therapeutic strategies4–6. Some differences exist between human RP and rodent models 
of retinal degeneration; for instance, the progression of photoreceptor loss takes place in a periphery-to-center 
gradient in humans and it is opposite (i.e. center-to-periphery) in rodents. This reflects the fact that in humans 
rods predominate in the periphery of the retina, whereas in rodents (which miss a fovea and have very few cones) 
these cells reach the highest density in the central retina.
More importantly, in most of the rodent models of the disease, photoreceptor degeneration starts when retinal 
development is still ongoing, unlike what observed for human RP, which typically develops in young adulthood. 
Actually, in rodents, photoreceptor-specific genes become expressed typically during the second week of postna-
tal life, when retinal cells are still dividing and synaptic connections actively forming. Thus, genetic models of RP 
are limited by the fact that some of the effects on retinal morphology and function could be caused by incorrect 
or incomplete retinal development rather than by the process of retinal degeneration per se7. Human typical RP is 
not a developmental disease and therefore most animal models do not mimic faithfully the human condition8,9.
Adequate models of RP, able to mimic the pathology more closely to the human counterpart (albeit on a 
faster temporal scale) are necessary to understand the neurobiology of this disease and test potential therapeutic 
strategies.
Few inducible mouse models of RP have been developed, which however are limited by the non-tissue specific 
expression of the underlying mutation10–12.
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Other inducible models have been generated using pharmacological agents such as iodoacetic acid (IAA), 
N-methyl-N-Nitrosurea (MNU) or Sodium Iodate13–15. The limit of this drug-based approach is that, rather than 
a given cell type, all retinal cells are targeted, so that the effect might be aspecific. This is very different from natu-
ral mutations responsible for RP, which are usually highly selective for both cell types and mechanisms of action. 
Moreover, a general toxicity is reported when the drugs are supplied by intravenous or intraperitoneal delivery16.
In this study we generated an inducible model of retinal degeneration that bypasses the window of retinal 
development. We exploited the bacterial toxin Cytotoxic Necrotizing Factor 1 (CNF1) to induce a primary, 
photoreceptor-specific damage in adult rats.
CNF1 is a protein toxin of approximately 110-kDa from pathogenic strains of Escherichia coli that acts as a mod-
ulator of the family of Rho GTPases (encompassing Rho, Rac and Cdc42 subfamilies), inducing actin reorganiza-
tion in stress and retraction fibers17. CNF1 acts by deamidating a specific glutamine residue (glutamine 63 in RhoA 
or its homolog in other Rho proteins)18 to glutamate, leading to the inhibition of the intrinsic (and GAP-stimulated) 
GTPase activity. Therefore, GTP hydrolysis is blocked, with a persistent effector activation that has been detected 
up to several weeks following one single CNF1 brain injection19. Subsequent to deamidation by CNF1, cellu-
lar Rac1 is ubiquitinated (and subsequently degraded) by a proteasome-dependent mechanism20,21. Thus, the 
net result of CNF1 treatment depends on the balance between activation and degradation of its effectors22,23. 
A similar toxin, Cytotoxic Necrotizing Factor Y (CNFY), is produced by entheropathogenic strains of Yersinia 
pseudotuberculosis. Contrary to CNF1, CNFY is a selective activator of RhoA, RhoB and RhoC, and can be used 
as a powerful tool for constitutive RhoA activation without concomitant activation of Rac1 or Cdc4220,24.
Here we found that a single intravitreal injection of CNF1 was sufficient to induce a primary photoreceptor 
damage, resulting in a retinal degeneration model that recapitulates some of the main features of RP, although 
cone loss was observed to occur concomitantly to the degeneration of rods.
Results
Induction of retinal degeneration with a single CNF1 intraocular injection. We tested the effects 
of different CNF1 doses injected intraocularly in Long Evans rats to set up optimal conditions in which retinal 
photoreceptors (PR) are the primary target of the toxin.
Escalating doses (0.1, 1, 3 and 10 nM) of the toxin were injected in rat eyes and the effects assessed 14 days 
after injections. An evident dose-dependent effect of the molecule could be observed, with progressively more 
severe patterns of retinal degeneration at higher concentrations, resulting in major retinal cell degeneration and 
loss of laminar structure at 10 nM (see Supplementary Fig. S1).
While doses of the toxin 3 nM or higher induced nonspecific degeneration of all retinal cell types, lower doses 
produced selective abnormalities in the photoreceptor layer, indicating that these cells are the most sensitive to 
dysregulation of Rho GTPase signaling in the retina. Because a moderate and progressive pattern of retinal degen-
eration was desirable, for possible use in rescue studies, we choose to employ 2 nM CNF1 for further experiments. 
Afterwards, we used morphological, biochemical and functional tools to analyze systematically the obtained 
paradigm of retinal degeneration.
Histopathological changes in CNF1-treated retinas. Three time points (i.e. 48 h, 7 days and 14 days 
post injection), corresponding to early, intermediate and late stages of retinal degeneration, were chosen to ana-
lyze CNF1-treated eyes, and evaluate the ability of CNF1 treatment to reproduce typical features of retinal degen-
eration of genetic origin.
Outer retina. Early effects of CNF1 are primarily visible in the outer retina, where a characteristic undula-
tion of the outer limiting membrane is observed as early as 48 h after injection (see Fig. 1, panels A, B and F). 
Photoreceptors begin to die as shown by the appearance of pycnotic nuclei (indicative of DNA condensation), and 
the outer nuclear layer (ONL) starts to lose its regular organization. A reduction of the ONL thickness (from 10 
to 5 rows of nuclei in the center) is visible 7 days after treatment (see Fig. 1, panels C and G). Fourteen days after 
treatment, only few photoreceptors remain; some of them appear clustered in typical rosettes, in which surviving 
cells become organized circularly around a central core. They are surrounded by remnant, displaced inner retinal 
neurons. The outer plexiform layer gradually disappears and the laminar organization of the retina is irreversibly 
lost (see Fig. 1, panels D and H). Retinal degeneration progresses from the center to the periphery, coherently 
with genetic rodent models of the pathology (see Fig. 2, and Supplementary Figs S3 and S4, panels A and C).
Inner retina. Following the initial phase of photoreceptor death and accompanying the final stages of ONL 
progressive thinning, inner retinal neurons undergo phases of reactive and regressive remodeling, although no 
reduction of INL thickness is observed (see Supplementary Fig. S3, panel B). Specifically, 7 days after injection, 
dendritic sprouting of bipolar cell is clearly visible (see Fig. 3, panel B). Sprouts are short, dendritic branches 
pointing toward the outer retina. However, with the progression of retinal degeneration, second order neurons 
(both rod bipolar and horizontal cells) retract their dendrites while their cell bodies become misplaced between 
the INL and those of remnant photoreceptors (see Fig. 3, panel C). Cholinergic (ChAT) bands, formed by the 
dendrites of starburst amacrine cells, remain normally positioned at 1/3 and 2/3 of the inner plexiform layer and 
maintain a parallel course even when the outer retina has totally degenerated. However, ChAT bands are abnor-
mally wavy along the tangential plane (see Fig. 4).
Ganglion cells and the ganglion cell layer appear less affected by retinal degeneration, i.e. the general morphol-
ogy of ganglion cells and their dendritic lamination in the IPL do not show major abnormalities.
Gliosis. CNF1 injections cause a robust activation of retinal glial cells. Müller cells show increased reactivity for 
GFAP all over the retinal surface and increased thickness of the radial processes. Microglia also switches from 
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the quiescent, ramified morphology, to the amoeboid shape typical of the phagocytic status (see Fig. 5, panel B). 
Activated microglial cells are found mainly in the outer retina and are evidently committed to engulf the nearby 
dying photoreceptors. This observation confirms that the latter are the main cell population undergoing cell death 
upon CNF1 injection.
Because of extensive retinal morphological rearrangements, we investigated whether CNF1 treatment induced 
mitosis in retinal and/or in microglial cells using an antibody specific for the cell division marker Histone 3 phos-
phate. No active mitosis was found in CNF1 treated (or in control) retinas; the retina from a 1-day old rat used as 
positive control (see Supplementary Fig. S5).
Functional analysis of CNF1-induced retinal degeneration. CNF1 reduces both scotopic and pho-
topic electroretinogram (ERG) responses.
ERG recordings in CNF1 injected and control eyes clearly demonstrated the functional consequences pre-
dictable on the basis of the morphological analysis, and namely a reduction in the amplitude of both scotopic and 
photopic responses as early as 48 h after CNF 1 treatment (Fig. 6A–E).
The amplitude of the ERG recorded from the eyes treated with the toxin appeared further reduced at the sub-
sequent time point examined (7 days after injection, Fig. 6F–J) and the ERG was completely suppressed 14 days 
after treatment (Fig. 6K,L). Figure 6E–J shows how the amplitude of both scotopic and photopic ERGs decreases 
in time with a similar time course both at 48 h and 7 days, indicating that the toxin affects similarly rods and 
cones. Furthermore, the ratio of scotopic b/a wave measured at 48 h and 7 days in control and in treated animals is 
not significantly changed, suggesting that the target of the toxin is mainly directed to photoreceptors rather than 
to second order neurons (see Supplementary Table S4).
Rac/Cdc42 are involved in CNF1-induced retinal degeneration. To demonstrate activation of Rho 
GTPase-dependent signaling pathways in CNF1-treated retinas, we assessed phosphorylation of LIMK1, one 
of the key steps in Rho- and Rac-dependent reorganization of the actin cytoskeleton. Indeed, two downstream 
effectors of Rho GTPases, P21 Protein (Cdc42/Rac)-Activated Kinase (PAK1) and Rho-associated protein kinases 
(ROCK), activate LIMK1 by phosphorylation at Thr-508. We therefore assessed the distribution of phospho-
rylated LIMK1 in control and CNF1-treated retinas at 48 h (see Fig. 7, panel B) using immunocytochemistry. 
We found robust labelling for activated LIMK1 in the rod outer segments in CNF1-injected, but not control, 
Figure 1. Morphological effects of CNF1 on the outer retina. Upper row: rod outer segments are stained 
in green with rhodopsin, and cones outer segment are stained in red by S and M/L wavelength cone opsin 
antibodies. Bottom row: cones are stained in red with cone arrestin, and photoreceptor terminals in green with 
PSD95. Nuclei are stained in blue with Hoechst dye. (A,E) control retinas. (B–D,F–H) CNF1 treated retinas 
harvested 48 hr (B,F), 7 days (C,G) and 14 days (D,H) post injection. Note the irregular course of the outer 
retina at early stages (B,F) and the uneven reduction of the ONL (G). Retinal organization appears profoundly 
altered at 14 days (D,H) with remnant photoreceptors dispersed in the INL and clustered in rosettes (arrows in 
D,H). Abbreviations here and in the following pictures: ONL, OPL: outer nuclear/plexiform layer. INL: inner 
nuclear layer; GCL: ganglion cell layer; OLM: outer limiting membrane; PRs: photoreceptors.
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samples (see Fig. 7, panel A). Relative measurements of fluorescence intensity in the layer of photoreceptor outer 
segments show statistically significant increase of PLIMK1 signal in CNF1 treated retinas (Two-tailed Student T 
test. P = 0.0036).
It should be noticed that activation of LIM kinase 1 is visible even in retinal regions where, 48 hours after 
injection, the undulation of the outer limiting membrane (OLM) is still minimal or absent. This suggests that the 
activation of Rac1 and Cdc42 pathways precedes retinal degeneration.
To narrow the search of possible molecular effectors of the retinal degeneration induced by CNF1, we took 
advantage of Yersinia pseudotubercolosis Cytotoxic Necrotizing Factor (CNFY), a toxin that selectively activates 
RhoA, but not Rac/Cdc4224. The toxin was injected under the same conditions used for CNF1, and treated and 
control eyes were collected after 14 days.
CNFY did not cause any adverse effect on the morphology of the retina, which remained virtually unchanged 
in its fine structure and lamination (Supplementary Fig. S7). These data suggest that the observed effects of CNF1 
on the retina depend upon the activation of Rac1 and/or Cdc42 GTPases, while a role of RhoA can be excluded.
CNF1 induces oxidative stress in retina. It is known that Rac1 is a component of NADPH oxidase that 
produces reactive oxygen species (ROS) in non-phagocytic cells. Indeed, it has been shown that its inactivation in 
rod photoreceptors makes these cells more resistant to photo-oxidative damage25.
Figure 2. Centre to periphery retinal degeneration 7 days after toxin injection. Panels (A,B) show the 
same area of a 7 days post CNF1 injection retina, viewed in fluorescence (A) and in bright field illumination 
with Nomarski optics (B). In A, nuclei are stained blue with Hoechst dye and cones in red with cone-arrestin 
antibodies. Double headed arrows in A highlight the different width of the ONL in peripheral (left) and central 
(right) retinal regions.
www.nature.com/scientificreports/
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We hypothesized that Rac1 constitutive activation following CNF1 treatment induced and increase in ROS 
and in retinal oxidative stress, contributing to primary photoreceptor death in our inducible model of retinal 
degeneration.
We found that retinas treated with CNF1 do exhibit a more intense dihydroethidium (DHE) staining com-
pared to the opposite, control retinas (see Fig. 8). The intensity of fluorescence DHE staining found in CNF1 
injected retinas is, on average, twice as bright as controls, indicating the presence of higher amounts of ROS in the 
toxin-exposed preparations (Two-tailed Student t test. P = 0.000609).
In summary, a single, 2 nM injection of CNF1 in the adult rat eye leads to a progressive retinal degeneration 
that starts from the photoreceptor layer and progresses in time toward the inner retina. This paradigm of retinal 
decay is associated to increased levels of ROS, appears independent from the activation of RhoA but is linked to 
Rac1 and Cdc42 activation, and is paralleled by profound abnormalities of the retinal ERG, which progressively 
becomes extinct.
Discussion
We successfully implemented a paradigm of retinal degeneration that summarizes key features of typical retinitis 
pigmentosa (RP), and specifically:
Figure 3. Morphological effects of CNF1 in the inner retina. Rod bipolar cells are stained by PKC antibodies 
(red signal); presynaptic glutamatergic terminals are stained by Bassoon (green signal). (A) Control retina. 
(B,C) CNF1 treated retinas. Remodeling of bipolar cells is visible beginning 7 days after treatment, in the 
form of dendritic sprouting (arrows in B and inset). 14 days after toxin injection, the dendrites of rod bipolar 
cells have completely retracted (C). Because of photoreceptors have died out (inset), Bassoon staining in their 
presynaptic terminals in the OPL is not detectable at this stage.
Figure 4. Retinal degeneration following CNF1 administration proceeds from the outer to the inner retina. 
Red: ethidium nuclear staining. Green: ChAT staining of cholinergic amacrine cells. (A) Control retina.  
(B) CNF1-injected retina, 14 days after injection. The distinction between ONL and INL has been lost, and yet 
the cholinergic bands are still clearly visible in B. Sparing of the innermost retina is typical of the RP phenotype.
www.nature.com/scientificreports/
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- Retinal degeneration can be induced in young adult animals, similarly to what observed in humans, for which 
the typical age of RP manifestation is late adolescence, outside the window of retinal development;
- Photoreceptors are the cells primarily affected. These cells undergo a process of progressive death;
- A center to periphery gradient in the onset of retinal morphological abnormalities is clearly observed;
- A close correspondence of anatomical and electrophysiological (ERG) findings is found;
- ERG data indicate the toxin effects are mainly on photoreceptors, albeit without a preference for rods or cones.
- Typical remodeling (sprouting, dendritic atrophy, cell body misplacement etc.) of second order neurons (with 
a sparing of innermost retinal cells) is observed following photoreceptor death;
- The severity of the retinal degeneration depends strictly on the dose of toxin used and progresses over time for 
a given dose.
We noted that the undulation of the outer limiting membrane and photoreceptor death began 2 days after 
injection, while sprouting of second order neurons was detected 7 days after treatment. These data suggest that 
remodeling of the inner retina is a secondary effect of the death of photoreceptors (like in RP), rather than caused 
by a direct action of the toxin on second order neurons. This interpretation is supported by the early and robust 
activation of LIMK1 in rod outer segments (but not in the inner retina) following CNF1 treatment (see Fig. 7).
Because we could demonstrate that CNF1 treated retinas showed higher levels of ROS compared to controls, 
we suggest that a possible mechanism of action of CNF1 on the retina involves the constitutive activation of 
Rac1, which in non-phagocytic cells is part of the enzymatic complex of NADPH oxidase. This would lead to 
the observed increment of oxidative byproducts. This could also explain why the primary effects of the toxin are 
detected selectively in photoreceptors: these cells are known to be highly vulnerable to photo-oxidative stress. 
This is in line with the finding that depletion of Rac1 in mouse rods makes them more resistant to photo-oxidative 
damage25 and that persistent activation of Rac1 obtained with transgenesis leads to retinal degeneration in 
mice26,27. It is important to note that CNF1 action depends on the balance between activation and degradation, 
and that CNF1-activated Rac1 is known to be eliminated by a proteasome-dependent mechanism. Thus, we can-
not exclude that the progression of degeneration at late stages is paradoxically caused by insufficient levels of Rho 
GTPases.
Contrary to Rac1 depletion studies, experiments performed to decrease the expression of Cdc42 from the 
retina have led to very different results. Cdc42 is necessary for the proper development of the retina28, while its 
removal in adult animals has neither adverse effects, nor exerts a protective action toward light induced retinal 
degeneration29. We found that a selective RhoA activation is not able, by itself, to induce retinal degeneration, as 
retinas treated with CNFY do not show any abnormality. Altogether, these data suggest that Rac1 activation in 
photoreceptors is the primary event leading to RP-like retinal reorganization following CNF1 treatment.
CNF1 has been used experimentally to manipulate adult neurons as well as to ameliorate the outcome of CNS 
pathologies, such as Rett syndrome and Alzheimer Disease (AD), because of its ability to promote neuronal plas-
ticity and to protect astrocytes22,30.
It might seem surprising that the same toxin could exert beneficial effects on some of the abnormalities found 
in Rett syndrome or AD, while exerting degenerative effects on photoreceptors. However, in the case of Rett syn-
drome, CNF1 was used to regulate cytoskeleton assembly of dendritic spines in a system in which a physiological 
Rho GTPase activity was defective30. Conversely, in the case of CNF1 eye injections, we observe that the toxin 
Figure 5. Activation of macro and microglia upon CNF1 injection. (A) Muller cells reactive gliosis 14 days 
post CNF1 injection. Red: GFAP; green: rhodopsin staining. Arrows point to clusters of residual photoreceptors 
(green). (B) Retinal whole mount stained with Iba1 antibody against microglia. Cells are in the typical 
amoeboid, active shape. The focal plane is in the outer retina. The inset shows an example of a quiescent, 
ramified microglial cell from a control retina.
www.nature.com/scientificreports/
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Figure 6. Functional effects of CNF1 toxin investigated by ERG recordings 48 h and 14 days after injection. 
(A,B) Representative example of scotopic and photopic ERG recordings (black trace: control eye, red trace: 
CNF1 injected eye) after 48 h. (C,D) Sensitivity curves (the amplitude as function of increasing intensity 
of light) of a-wave and b-wave from scotopic (C) and photopic (D) ERG. (E) Percentage residual response 
(compared to control eye) of scotopic and photopic ERG response (solid line = average control response, dotted 
line = average scotopic response, dashed line = average photopic response). (F,G) Representative example of 
scotopic and photopic ERG recordings after 7 days. (H,I) Sensitivity curves of a-wave and b-wave from scotopic 
(H) and photopic (I) ERG. (J) Percentage residual response (compared to control eye) of scotopic and photopic 
ERG response. (K,L) Representative example of scotopic and photopic ERG recordings after 14 days.
www.nature.com/scientificreports/
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impacts on photoreceptors, which have high metabolic rates and continuous membrane turnover and are there-
fore highly sensitive to oxidation and cytoskeletal changes. CNF1 preferential action on photoreceptors may be 
due to either uptake of the bacterial toxin, which occurs via receptor-mediated endocytosis, or cell-specific sensi-
tivity to Rho GTPase perturbation. Two CNF1 receptors, laminin receptor31 and Lutheran adhesion glycoprotein/
basal cell adhesion molecule (Lu/BCAM)32 have been recently identified but it is not known whether they are 
predominantly expressed in photoreceptors. Specificity of CNF1 action in photoreceptors may also result from a 
Figure 7. Activation of Rac1 and Cdc42 downstream effector. Immunocytochemistry for phosphorylated 
(Thr508) LIM Kinase1 (green), 48 hrs post injection of vehicle (A) or CNF1 (B). Quantification of fluorescence 
shows that the intensity of staining in toxin injected retinas is 2.6 times brighter with respect to control 
preparations in the layer of photoreceptor outer segments (OS). (C) Diagram of mean values of fluorescence 
intensity in CNF1 (red) and control (black) preparations. Error bars represent s.e. of the mean.
Figure 8. DHE assay on retinal sections 24 hours after vehicle (A) or CNF1 (B) intraocular injections. In 
the presence of ROS, DHE is converted to ethidium, which stains DNA, producing a red fluorescence signal. 
Quantification of fluorescence shows that the intensity of staining in toxin-injected retinas is twice as bright 
with respect to control preparations (C). Bars represent mean values of fluorescence intensity; error bars 
represent s.e. of the mean.
www.nature.com/scientificreports/
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selective vulnerability: these metabolically very active cells are likely sensitive to dysregulation of intracellular sig-
naling, so that continuous activation of Rho GTPase signaling and changes in cytoskeletal organization may lead 
to their degeneration. This interpretation is supported by the cytotoxic effects of CNF1 on proliferating cells such 
as glioma cells33. In addition, mutations in proteins involved in the dynamics of actin cytoskeleton lead to severe 
photoreceptor phenotypes and retinal blindness, as it is the case of ciliopathies including Usher syndrome34.
Altogether, we believe that the specific, toxin-inducible model of retinal degeneration described here offers 
several advantages, including the possibility to be exported to mammals of larger size, like rabbits and pigs. These 
are reference species for pharmaceutical therapeutic approaches in ophthalmology. In perspective, CNF1-induced 
retinal degeneration could be also implemented in monkeys (which otherwise do not develop RP), a model sys-
tem for testing therapies close to human translation. Noticeably, rats treated with CNF1 did not show damages 
to other organs or general behavioral abnormalities, unlike drug-induced models described in other studies16. 
Indeed, albeit Rho GTPases are ubiquitously expressed in cells, the CNF1 dosage used here appears to target 
primarily photoreceptors. Higher doses do affect all retinal layers simultaneously, as shown in Supplementary 
Fig. S1.
Because CNF1 induces a rapid and quite specific process of photoreceptor death, it could be useful in cell 
transplantation studies to eliminate residual, abnormal photoreceptors, favoring the implant of healthy precur-
sors. This process would also be favored by the observation that CNF1 decreases the stability of the outer limiting 
membrane, a significant physical barrier to the migration and integration of precursors in the adult host retina35.
Finally, mechanistic studies on CNF1 toxin might reveal unknown pathways existing in normal photore-
ceptors that are susceptible to degeneration of these cells if altered or mutated. For example, a link has been 
established between NADPH oxidase and progressive retinal degeneration36,37 while a direct connection has been 
shown between Rac1 activation and retinal degeneration in mouse models38.
CNF1 signaling is composed by various molecular effectors. Clearly, photoreceptors are highly sensitive to 
these molecules whose balance might affect their survival. It is possible that mutations of this molecular machin-
ery are responsible for forms of RP for which the parent mutation has not been identified yet. This study suggests 
searching for candidate disease genes among molecules belonging to the CNF1 signaling cascade36, hopefully 
contributing to the still incomplete catalogue of genes for inherited retinal diseases (see https://sph.uth.edu/
retnet/sum-dis.htm).
Methods
Animals. All the experimental procedures were in accordance with European and Italian laws regulating the 
experimental use of animals for research. All experimental protocols were approved by the Italian Ministry of 
Health and by the CNR Neuroscience Institute Animal Care and Use Committee (Protocol #Strettoi14D). Adults 
Long Evans Hooded rats (age 4–12 months) were used in this study. A total of 24 rats were used to set the toxin 
dosage able to induce a retinal degeneration mimicking an RP like phenotype. A dosage of 2 nM CNF1 was 
chosen for immunohistochemistry assays and photopic ERG recordings, then using a total of additional 34 rats 
(19 for morphological experiments and 15 for ERG recordings, respectively).
CNF1 ocular injections. CNF1 was purified as described previously29. For intraocular injections, the toxin 
was diluted in Tris HCl 1 M pH 7.4 from the initial concentration of 870 nM. After dilution, the toxin was stored 
at 4 °C and used within a month.
For intraocular injections, individual rats were pre-anesthetized with a gaseous mixture of 3–4% isoflurane in 
oxygen. The rats were then moved under a surgical microscope where the anesthesia, channeled through a mask, 
was maintained with a mixture of isoflurane in oxygen at 2.5%. Intraocular injections were performed in the 
vitreous body, using a glass capillary filled with the toxin and hand driven by an oil micromanipulator. A volume 
of 2 μ l was injected at the ora serrata. Control injections consisted of equal volumes of vehicle only, or of boiled 
volumes of the toxin. Gaseous anesthesia allows recovery of the animals within minutes and the animals were 
returned to their cages after the injections.
Retina explants. Rats were deeply anesthetized with intraperitoneal injections of avertin (6 gr of 2,2,2 tribro-
moethanole in 1% tert-amyl alcohol) at dose of 10 ml/Kg of body weight.
Eyes were rapidly enucleated, marking the dorsal pole with a skin marker, and immersion-fixed in 4% para-
formaldehyde (PFA) in 0.1 M phosphate buffer (PB) for 30 minutes. The animals were sacrificed with an overdose 
of the same anesthetic. The eyes were then dissected to remove lens and cornea, thus obtaining eye-cups. A refer-
ence cut was made in correspondence of the dorsal pole, both in the sclera and the retina.
Eyecups were post-fixed for 30 minutes in the same fixative, then washed extensively in PB, infiltrated with 
30% sucrose in the same buffer, followed by OCT embedding medium (Sakura, Tissue-Tek® O.C.T™ cat #4583). 
Finally, the eyecups were frozen in cold isopenthane and serially sectioned at a cryostat in 14 μ m thick sections.
The eyes used for dihydroethium (DHE) assay were rapidly enucleated, embedded in OCT and immediately 
frozen in cold isopenthane, without fixation.
Fluorescence Immunocytochemistry (ICCH). To study the morphology and survival rates of retinal 
cells in preparations from treated and control rats, we used ICCH with cell-type specific antibodies followed by 
confocal microscopy.
Cryostat retinal sections were incubated in blocking solution containing 0,3% Triton X-100, 5% goat or 
donkey serum, 0.01 M PBS (pH 7.4), at RT °C for 2 hours. Primary antibodies were diluted in the same buffer 
with 0,1% Triton X-100, 1% goat or donkey serum and revealed with anti-mouse/anti-rabbit Alexa Fluor 488 
or anti-mouse/anti-rabbit Rhodamine RedX-conjugated secondary antibodies (all diluted 1:1,000), (Jackson 
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Immunoresearch laboratories, USA). Retinal sections were counterstained with ethidium homodimer 1, or with 
YOYO-1 or with Hoechst (all diluted 1:1,000) to reveal nuclei (Invitrogen, Life Technologies).
For rod and cone identification, antibodies against rhodopsin (Sigma, O4886), cone opsins (Merk-Millipore, 
AB5407 and AB5405) and cone arrestin (Merk-Millipore, AB15282) were used. To study the morphology of 
inner retinal neurons and synapses, antibodies against PKC alpha (Sigma, P4334 or P5704), Smi32 (Covance, 
Smi32R), Bassoon (Enzo Life Science, ADI-VAM-PS003), Ribeye (BD Biosciences, 612044), PSD95 (AbCam 
Ab13552), Chat (Merck-Millipore, AB144P) and anti synaptotagmin 2 (Znp1) (Zebrafish International Resource 
Center, USA) were used. Glial activation was assessed with antibodies against GFAP (Sigma, G9269) and Iba1 
(Wako, 019–19741). Mitotic activity was analyzed with an antibody marker of cell division, Phospho Histone H3 
(Merk-Millipore, 06–570). Activation of Lim Kinase 1 was assessed with an antibody recognizing its phosphoryl-
ated form at threonine 508 (Sigma Aldrich, SAB4300103). Retinal sections and whole mount retinas were exam-
ined with a Zeiss Axio Plan microscope and acquired in brightfield with a Zeiss AxioCam camera or with a Zeiss 
Imager Z2 fluorescence microscope equipped with an ApoTome 2 system. Systematic imaging was also obtained 
with a Leica TCS-SP confocal microscope. Acquisition parameters (width along the z-axes, laser intensity, photo-
multiplier gain and pinhole size) were kept constant for all the samples examined.
Nuclear layers measurements. Retinal sections from control and CNF1 injected eyes at different time 
points (48 h, 7day and 14 days after injection) were stained with micromolar solution of Hoechst nuclear dye 
(Invitrogen, Life Technologies) and imaged with a Zeiss Axioplan epifluorescence microscope equipped with a 
Zeiss Axio Cam camera and a 20x objective. Sections from 3 different eyes (from 3 different CNF1 injected and 
control animals) were used for each time point; 3 near-equatorial sections per retina were measured, sampling 
both central and peripheral eccentricities.
Measures of outer and inner nuclear layer thickness were made on sections images with MetaMorph program; 
the statistical analysis, t-test, was performed with SigmaPlot 12.
Histochemistry: Dihydroethidium (DHE) assay. To detect retinal oxidation, we used a histochemical 
assay based on Dihydroethidium (Sigma Aldrich, Cat #37291), a reduced form of ethidium homodimer. In the 
presence of ROS, DHE is oxidized to ethidium with specific DNA intercalant ability and red fluorescence.
Dihydroethidium powder was resuspended in dimethilsulfoxide at 10−2 M and stored at − 20 °C. As dihydro-
ethidium could oxidize in the presence of light, all the steps of the assay were conducted in the dark. Cryostat 
sections from both CNF1 and vehicle treated eyes were mounted on each glass slide to minimize experimen-
tal variability. Sections were washed 3 × 10 minutes with PBS and incubated with DHE, diluted in PBS to final 
concentration of 10−6 M, at 37 °C for 30 minutes. Afterwards, the sections were washed 3 × 10 minutes in PBS, 
mounted and immediately examined by confocal microscopy.
As for ICCH, acquisition parameters were kept constant for all the samples examined.
Quantification of fluorescence and statistical analysis. Confocal images obtained from 
phospho-LimK1 and DHE experiments from vehicle and CNF1 treated retinas were analyzed with a specific 
routine of MetaMorph program for fluorescence quantification. Measures obtained from images of 10 sections for 
each experimental group were statistically compared using Sigma Plot 12 software. For each experimental group, 
a normality test was run, followed by two tailed t-test (alpha = 0.05).
Electroretinogram (ERG). Rats were dark-adapted overnight and then anesthetized with an intraperitoneal 
injection of 20% urethane (1 ml/kg body weight), mounted in stereotaxic position and setup for ERG recordings39. 
Gold extra-corneal electrodes were used, while the ground electrode was a gold plate placed in the animal mouth. 
Body temperature was maintained at 37 °C. Pupils were dilated by administration of tropicamide (1%) eye drops, 
and the cornea was kept moist with a methylcellulose solution. An electronic flash unit generated a light stimulus 
of 492 nm whose energy decayed with a τ of 1.7 ms. Full-field stimulation was achieved using a Ganzfeld sphere, 
and flash intensities were attenuated by neutral-density filters. Rats were subjected to thirteen different flash 
intensities for scotopic ERG and seven for photopic ERG, each repeated five times, with an interstimulus interval 
that ranged from 20 s for dim light to 1 min for the brightest flashes40. The flash luminance was measured at the 
corneal plane in photometric units (cd·s/m2) using a Minolta CS100 photometer with a scotopic filter. Responses 
were differentially amplified, band-pass-filtered at 0.3–500 Hz, digitized at 0.25- to 0.5-ms intervals, and stored on 
disk for processing. The amplitude of the a-wave was taken as the difference between baseline and the value after 
7 ms from flash, whereas the amplitude of the b-wave was measured from the minimum value of the a-wave to the 
peak of the b-wave. Isolated cone components were obtained by superimposing test flashes on a background of 
saturating intensity for rods (30 cd/m2).
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